GABAergic Compounds Targeting Alpha-4 and Alpha-5 Receptors for Asthma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bronchoconstrictive diseases such as asthma lack effective pharmacologic approaches for acute airway smooth muscle relaxation, with limited options beyond α-adrenoceptor agonists and anti-cholinergics, and existing therapies fail to adequately address lung inflammation and autoimmune-related inflammation.
Innovation Solution
Development of novel GABAergic compounds that selectively target α4 and α5 subunits of GABAA receptors, reducing benzodiazepine-type CNS effects, which are administered to reduce airway constriction, lung inflammation, and disease development, formulated into pharmaceutical compositions for oral or aerosol administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If benzodiazepine-type compounds are used to relax airway smooth muscle, then airway relaxation is achieved, but CNS side effects occur
Solution Approach 1:
The patent applies local quality by designing compounds with selective affinity for specific GABAA receptor subunits (α4 and/or α5) expressed in airway smooth muscle, rather than acting on all GABAA receptors throughout the body. This subunit-selective approach provides localized therapeutic action in the lungs while minimizing systemic CNS effects.
Solution Approach 2:
The invention segments the GABAA receptor system by targeting specific subunit compositions (α4-containing and/or α5-containing receptors) that are preferentially expressed in airway smooth muscle. This segmentation allows selective modulation of airway tone without affecting CNS GABAA receptors that have different subunit compositions.
2Adaptability or versatility
If existing pharmacologic approaches (α-adrenoceptor agonists and anti-cholinergics) are used for acute airway constriction, then airway relaxation is achieved, but therapeutic options remain limited
Solution Approach 1:
The patent introduces a new therapeutic mechanism (GABAA receptor agonism) that is universally applicable to bronchoconstrictive diseases including asthma, COPD, and bronchopulmonary dysplasia. This expands the arsenal of available treatments beyond the existing two drug classes, providing versatile options for different clinical scenarios.
3Object-affected harmful factors
If current asthma treatments are used, then some symptom relief is achieved, but lung inflammation and autoimmune-related inflammation are not adequately addressed
Solution Approach 1:
The patent employs GABAA receptor activation as an intermediary mechanism to indirectly control inflammation. By activating GABAA receptors on airway smooth muscle and inflammatory cells, the compounds produce anti-inflammatory effects through downstream signaling pathways, providing a novel approach to inflammation control that complements existing anti-inflammatory therapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively relax airway smooth muscle, reduce lung inflammation, and mitigate disease progression by potentiating α-adrenoceptor-mediated relaxation and targeting specific GABAA receptor subunits, offering a new therapeutic option for bronchoconstrictive diseases and autoimmune-related lung inflammation.
Implementation Method 1
GABAergic compounds that bind to and activate GABAA receptors on airway smooth muscle cells
Implementation Method 2
potentiating α-adrenoceptor-mediated relaxation
Data Source
AI summary
Novel methods of treating inflammation and airway constriction using GABAergic compounds with reduced benzo-diazepine-like CNS activity are provided. Novel compounds which selectively target alpha-4 and alpha-5 GABAA receptors and methods of using those compounds to treat bronchoconstriction and inflammation are provided herein.